Your Health, We Care
Momelotinib is an OATP1B1/B3 substrate. Concomitant use with an OATP1B1/B3 inhibitor increases momelotinib maximal concentrations (Cmax) and area under the concentration-time curve (AUC), which may increase the risk of adverse reactions with Momelotinib. Monitor patients concomitantly receiving an OATP1B1/B3 inhibitor for adverse reactions and consider Momelotinib dose modifications.
Momelotinib is a BCRP inhibitor. Momelotinib may increase exposure of BCRP substrates, which may increase the risk of BCRP substrate adverse reactions. When administered concomitantly with Momelotinib, initiate rosuvastatin (BCRP substrate) at 5 mg and do not increase to more than 10 mg once daily. Dose adjustment of other BCRP substrates may also be needed. Follow approved product information recommendations for other BCRP substrates.
from FDA,2023.09
